Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Frazier & Co. Moves Into Technology Investing

This article was originally published in Start Up

Executive Summary

Frazier & Co.'s recent launch of Frazier Technology Ventures (FTV), a new technology fund that will apportion part of its portfolio to e-health/bioinformatic companies seems, at first blush, to come at a bit of an odd time. The volatility of the tech sector has many VCs reexamining their positions in that arena, with e-health financings particularly hard hit. Frazier & Co.'s move is also contrary to the general trend of VC firms choosing to specialize in either e-health or traditional health care investing. A number of health care firms, like Oak, Sequoia and Accel dropped health care entirely last year during the e-health boom. And Brentwood Ventures spun out separate IT and health care groups. But, according to Frazier & Co.'s management, their timing was just right and reflects both patience and careful planning. Moreover, they emphasize that the new fund, while within the Frazier & Company infrastructure, will, in fact, be invested independently by a group of Information Technology specialists.

You may also be interested in...

Earlybird Venture Capital LLC

Earlybird hopes to capitalize on the convergence of information technologies with health care. It sees these two sectors not as separate strands with fundamentally different investment strategies, but rather as areas whose increasing overlap presents a new pool of companies needing support with experience in both businesses, and, the contend, bi-continental reach.

AureoGen Biosciences Inc.

Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.

Pain Therapeutics

Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts